文献速递乳腺癌

高危乳腺癌区域放疗:大分割40Gy/15次对比常规50Gy/25次的III期随机试验

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.
PubMed 文献 · J Clin Oncol · 2026-07-23

丹麦乳腺癌协作组Skagen 1试验将2908例需区域放疗的高危乳腺癌患者随机分为50Gy/25次组与40Gy/15次组,主要终点为3年淋巴水肿。两组局部区域复发、远处复发、乳腺癌死亡及全因死亡均无差异。

要点

  • 40Gy/15次区域放疗3年淋巴水肿不劣于50Gy/25次,未增加水肿风险。
  • 两组局部区域复发、远处复发、乳腺癌死亡及全因死亡均无显著差异。
  • 高危乳腺癌区域放疗可采用40Gy/15次大分割方案。

核心结论

  • 40Gy/15次区域放疗未导致比50Gy/25次更多的淋巴水肿。
  • 两组局部区域复发、远处复发、乳腺癌死亡及全因死亡均无差异。

研究设计与样本

  • Skagen 1为III期非劣效随机试验,纳入高危乳腺癌需区域放疗患者。
  • 2015至2021年17个中心共2963例同意,意向治疗队列2908例,50Gy组1444例、40Gy组1464例。
  • 中位年龄57岁(范围23-86),主要终点为3年淋巴水肿,预设非劣效界值为40Gy组发生率最多超出5个百分点。

主要发现

  • 肿瘤结局中位随访5.25年(IQR 4.26-6.96),8年内局部区域复发HR 0.96(95%CI 0.62-1.51)。
  • 远处复发HR 1.10(95%CI 0.89-1.37),乳腺癌死亡HR 1.25(95%CI 0.93-1.66)。
  • 全因死亡HR 1.08(95%CI 0.85-1.36),均无随机分组差异。

关键数值与推荐

  • 非劣效界值:假设50Gy/25次3年淋巴水肿发生率10%,允许40Gy/15次最多超出5个百分点。
  • 8年内局部区域复发HR 0.96(95%CI 0.62-1.51),远处复发HR 1.10(95%CI 0.89-1.37)。
  • 乳腺癌死亡HR 1.25(95%CI 0.93-1.66),全因死亡HR 1.08(95%CI 0.85-1.36)。

临床怎么用

  • 高危乳腺癌区域放疗可考虑40Gy/15次大分割方案,不增加淋巴水肿且肿瘤结局无差异。
  • 该方案可作为50Gy/25次区域放疗的替代选择。

局限性

  • 中位随访4.1年(淋巴水肿)和5.25年(肿瘤结局),长期安全性及疗效仍需更久随访。
  • 非劣效界值预设为5个百分点,评价淋巴水肿的检测方法未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adjuvant radiotherapy for node-positive breast cancer (BC) using 50Gy/25fx has been Danish Breast Cancer Group (DBCG) standard. Hypofractionated radiotherapy based on 40Gy/15fx has been increasingly used; however, it is less frequently for locoregional therapy because of concern over more morbidity. DBCG Skagen trial 1 hypothesized that 40Gy/15fx did not cause more lymphedema than 50Gy/25fx 3 years after radiotherapy without compromising the pattern of failure. METHODS: Skagen trial 1 is a phase III, noninferiority trial randomly assigning high-risk BC patients with an indication for locoregional radiotherapy to standard 50Gy/25fx versus experimental 40Gy/15fx. The primary end point was arm lymphedema; assuming a 3-year incidence with 50Gy/25fx of 10%, noninferiority was predefined to maximum 5% excess incidence with 40Gy/15fx. Accrual continued until 3-year estimates were reported in 1,012 patients. RESULTS: Between 2015 and 2021, 2,963 patients consented from 17 centers; the intention-to-treat cohort comprised 2,908 patients: 1,444 had 50Gy (50%), and 1,464 had 40Gy (50%). The median age was 57 years (range, 23-86). At a median follow-up of 4.1 years (IQR, 3.0-5.0), the 3-year rates of lymphedema were 9.4% (50Gy) versus 8.0% (40Gy), odds ratio 0.84 (95% CI, 0.62 to 1.14), and P = .27, thus within the +5-percentage-point noninferiority margin. The median follow-up for cancer outcomes was 5.25 years (IQR, 4.26 to 6.96). Within 8 years, the hazard ratio for locoregional recurrence was 0.96 (95% CI, 0.62 to 1.51), that for distant recurrence was 1.10 (95% CI, 0.89 to 1.37), that for BC mortality was 1.25 (95% CI, 0.93 to 1.66), and that for all-cause mortality was 1.08 (95% CI, 0.85 to 1.36), thus all with no differences by random assignment. CONCLUSION: 40Gy/15fx for locoregional radiotherapy of BC did not result in more lymphedema compared with 50Gy/25fx. There were no differences in locoregional or distant recurrences, breast cancer mortality, nor all-cause mortality between the random assignment arms.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Offersen BV, Alsner J, Høgsbjerg K, et al. Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. J Clin Oncol. 2026. PMID: 42492022. doi:10.1200/JCO-25-02705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。